Target intelligence / Profile preview

Influenza A virus H5 hemagglutinin (H5 HA)

Target
H5 HA
Molecular classification
Receptor, Other
01

Overview

The H5 hemagglutinin (HA) is a major surface glycoprotein of the highly pathogenic H5 subtype of influenza A viruses, such as H5N1. It plays a critical role in the early stages of viral infection by mediating both host cell receptor binding and subsequent membrane fusion. Specifically, the HA1 subunit of the homotrimeric protein binds to sialic acid receptors on host cells, while the highly conserved HA2 subunit undergoes conformational changes at low pH to facilitate the fusion of the viral envelope with the endosomal membrane. Because of its essential role in viral entry, H5 hemagglutinin is a primary target for the development of vaccines, neutralizing monoclonal antibodies, and small-molecule entry inhibitors. Therapeutic agents targeting this protein, such as the broadly neutralizing antibodies diridavumab (CR6261) and MEDI8852 (FI6v3), aim to block viral entry or prevent the conformational changes required for membrane fusion. However, the high plasticity of the hemagglutinin protein, driven by antigenic drift and shift, presents a significant challenge, often leading to the emergence of drug-resistant variants and requiring the development of universal vaccines or therapies targeting highly conserved regions like the stem domain.

Other names
H5 hemagglutininH5HAHemagglutinin H5Influenza A virus H5N1 hemagglutininHA protein of H5 influenza virusHemagglutinin protein of H5 influenza virus
02

Mechanism of action

Inhibition of viral entry by blocking host cell receptor binding or preventing the conformational changes required for membrane fusion.

03

Biological functions

Immune responseOther
04

Disease associations

InfectionOther
05

Safety considerations

Antigenic driftAntigenic shiftDrug resistance mutationsPoor immunogenicity of H5 vaccinesAntibody-dependent enhancement (ADE)Hypersensitivity reactions
06

Interacting drugs

Diridavumab (CR6261)

6 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HI) titerMicroneutralization (MN) titerAnti-H5 antibody titerViral load

Beyond the preview

Go deeper on Influenza A virus H5 hemagglutinin (H5 HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus H5 hemagglutinin (H5 HA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call